financetom
Business
financetom
/
Business
/
OpenAI seeks to dismiss all of Musk's claims in lawsuit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OpenAI seeks to dismiss all of Musk's claims in lawsuit
Mar 5, 2024 7:04 PM

(Reuters) - ChatGPT-maker OpenAI on Tuesday refuted Elon Musk's claims that the startup abandoned its original mission to develop artificial intelligence for the benefit of humanity and not for profit.

OpenAI said it intends to move to dismiss all of Musk's claims in a blog post. Musk filed a lawsuit against the Microsoft ( MSFT )-backed company last week alleging breach of contract, and saying the startup is now focused on making money.

(Reporting by Abinaya Vijayaraghavan in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Advance Premarket Friday
Sector Update: Consumer Stocks Advance Premarket Friday
May 31, 2024
09:19 AM EDT, 05/31/2024 (MT Newswires) -- Consumer stocks were advancing premarket Friday as the Consumer Staples Select Sector SPDR Fund ( XLP ) was up 0.2% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) was marginally higher. Nordstrom ( JWN ) fell by more than 1% after it reported a fiscal Q1 adjusted net loss of...
Nvidia Isn't the Only Way to Play AI
Nvidia Isn't the Only Way to Play AI
May 31, 2024
09:23 AM EDT, 05/31/2024 (MT Newswires) -- Nvidia ( NVDA ) remains the dominant play in AI in the near-term, but there are other ways to play the AI story, according to The Compound and Friends podcast on Friday morning. Host Josh Brown says Nvidia ( NVDA ) will become larger than Apple ( AAPL ) on a market...
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints
May 31, 2024
09:23 AM EDT, 05/31/2024 (MT Newswires) -- Novartis ( NVS ) said Friday that the late-stage trial for its treatment for chronic myeloid leukemia, Scemblix, has met both of its primary endpoints. Scemblix demonstrated clinically significant efficacy that was better than select standard-of-care therapies of the same type, the drugmaker said. The drug's safety profile was consistent with previous studies...
Johnson & Johnson Closes Acquisition of Shockwave Medical
Johnson & Johnson Closes Acquisition of Shockwave Medical
May 31, 2024
09:26 AM EDT, 05/31/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that it has closed its acquisition of Shockwave Medical, which it said will operate as a business unit within Johnson & Johnson MedTech. The transaction is anticipated to dilute adjusted earnings per share by about $0.10 in 2024 and $0.17 in 2025 considering the impact...
Copyright 2023-2026 - www.financetom.com All Rights Reserved